Pathogenesis of NUT midline carcinoma

Annual Review of Pathology: Mechanisms of Disease

Volumn 7, Issue , 2012, Pages 247-265

  French, Christopher A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BET inhibitor; BRD4 NUT; Differentiation therapy; Histone acetyltransferase; Histone deacetylase inhibitor; http: www.NMCRegistry.org

Indexed keywords

ANTIINFLAMMATORY AGENT; BRD NUT PROTEIN; BRD3 NUT PROTEIN; BRD3 PROTEIN; BRD4 NUT PROTEIN; BRD4 PROTEIN; BROMODOMAIN AND EXTRATERMINAL DOMAIN CONTAINING PROTEIN INHIBITOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; NUT PROTEIN; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

ADENOSQUAMOUS CARCINOMA; CANCER DIAGNOSIS; CANCER SURVIVAL; CHROMOSOME 15Q; CHROMOSOME 19P; CHROMOSOME 9Q; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CYTOGENETICS; DIAGNOSTIC TEST; EWING SARCOMA; FUSION GENE; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; KARYOTYPE; LEUKEMIA; MOLECULAR GENETICS; NASOPHARYNX CARCINOMA; NEUROBLASTOMA; NUT MIDLINE CARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SQUAMOUS CELL CARCINOMA; UNDIFFERENTIATED CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; HISTONE DEACETYLASES; HUMANS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION;

EID: 84856857218     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-011811-132438     Document Type: Review

References (58)

1. Shehata BM, Steelman CK, Abramowsky CR, Olson TA, French CA, et al. 2009.NUTmidline carcinoma in a newborn with multiorgan disseminated tumor and a 2-year-old with a pancreatic/hepatic primary. Pediatr. Dev. Pathol. 13:481-85
2. Stelow EB, Bellizzi AM, Taneja K, Mills SE, Legallo RD, et al. 2008. NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. Am. J. Surg. Pathol. 32:828-34
3. French CA, Kutok JL, Faquin WC, Toretsky JA, Antonescu CR, et al. 2004. Midline carcinoma of children and young adults with NUT rearrangement. J. Clin. Oncol. 22:4135-39 (Pubitemid 41185183)
4. French CA. 2010. Demystified molecular pathology of NUT midline carcinomas. J. Clin. Pathol. 63:492-96
5. den Bakker MA, Beverloo BH, van den Heuvel-Eibrink MM, Meeuwis CA, Tan LM, et al. 2009. NUT midline carcinoma of the parotid gland with mesenchymal diffentiation. Am. J. Surg. Pathol. 33:1253-58
6. Ziai J, French CA, Zambrano E. 2010. NUT gene rearrangement in a poorly differentiated carcinoma of the submandibular gland. Head Neck Pathol. 4:163-68
7. Mertens F, Wiebe T, Adlercreutz C, Mandahl N, French CA. 2007. Successful treatment of a child with t(15;19)-positive tumor. Pediatr. Blood Cancer 49:1015-17 (Pubitemid 350022467)
8. Engleson J, Soller M, Panagopoulos I, Dahlen A, Dictor M, Jerkeman M. 2006. Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy. BMC Cancer 6:69
9. Liebertz DJ, Lechner MG, Masood R, Sinha UK, Han J, et al. 2010. Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1. Head Neck Oncol. 2:5
10. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. 2006. Human cancers express a mutator phenotype. Proc. Natl. Acad. Sci. USA 103:18238-42 (Pubitemid 44871642)
11. Bonnet D, Dick JE. 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopietic cell. Nat. Med. 3:730-37 (Pubitemid 27298715)
12. HuberMA, KrautN, BeugH. 2005. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17:548-58 (Pubitemid 41267170)
13. Thiery JP, Sleeman JP. 2006. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7:131-42 (Pubitemid 43278296)
14. Reynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, et al. 2010. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 29:2943-52
15. French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA. 2003. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 63:304-7 (Pubitemid 36152484)
16. French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ, et al. 2008. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27:2237-42 (Pubitemid 351483375)
17. French CA, Miyoshi I, Aster JC, Kubonishi I, Kroll TG, et al. 2001. BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). Am. J. Pathol. 159:1987-92 (Pubitemid 33104253)
18. Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, et al. 2011. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 71:2686-96
19. Haack H, Johnson LA, Fry CJ, Crosby K, Polakiewicz RD, et al. 2009. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am. J. Surg. Pathol. 33:984-91
20. Kubonishi I, Takehara N, Iwata J, Sonobe H, Ohtsuki Y, et al. 1991. Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res. 51:3327-28
21. Kees UR, Mulcahy MT, Willoughby ML. 1991. Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). Am. J. Pediatr. Hematol. Oncol. 13:459-64
22. Lee AC, Kwong YI, Fu KH, Chan GC, Ma L, Lau YL. 1993. Disseminated mediastinal carcinoma with chromosomal translocation (15;19). A distinctive clinicopathologic syndrome. Cancer 72:2273-76 (Pubitemid 23280160)
23. Vargas SO, French CA, Faul PN, Fletcher JA, Davis IJ, et al. 2001. Upper respiratory tract carcinoma with chromosomal translocation 15;19: evidence for a distinct disease entity of young patients with a rapidly fatal course. Cancer 92:1195-203 (Pubitemid 32861669)
24. Toretsky JA, Jenson J, Sun CC, Eskenazi AE, Campbell A, et al. 2003. Translocation (11;15;19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients. Am. J. Clin. Oncol. 26:300-6 (Pubitemid 36712648)
25. You J, Croyle JL, Nishimura A, Ozato K, Howley PM. 2004. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 117:349-60 (Pubitemid 38534541)
26. Moriniere J, Rousseaux S, Steuerwald U, Soler-Lopez M, Curtet S, et al. 2009. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 461:664-68
27. Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K. 2003. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. USA 100:8758-63 (Pubitemid 36899172)
28. Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. 1999. Structure and ligand of a histone acetyltransferase bromodomain. Nature 399:491-96 (Pubitemid 29258857)
29. Dey A, Ellenberg J, Farina A, Coleman AE, Maruyama T, et al. 2000. A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G2-to-M transition. Mol. Cell Biol. 20:6537-49 (Pubitemid 30650239)
30. Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. 2005. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNApolymerase II-dependent transcription. Mol. Cell 19:523-34 (Pubitemid 41140009)
31. Mochizuki K, Nishiyama A, Jang MK, Dey A, Ghosh A, et al. 2008. The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase. J. Biol. Chem. 283:9040-48
32. Yang Z, Yik JH, Chen R, He N, Jang MK, et al. 2005. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 19:535-45 (Pubitemid 41140010)
33. Lin YJ, Umehara T, Inoue M, Saito K, Kigawa T, et al. 2008. Solution structure of the extraterminal domain of the bromodomain-containing protein BRD4. Protein Sci. 17:2174-79
34. Ottinger M, Christalla T, Nathan K, Brinkmann MM, Viejo-Borbolla A, Schulz TF. 2006. Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest. J. Virol. 80:10772-86 (Pubitemid 44628923)
35. Reynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, et al. 2010. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 29:2943-52
36. Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Gonzalez A, et al. 2005. Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro. J. Med. Genet. 42:558-64 (Pubitemid 40993831)
37. Govin J, Lestrat C, Caron C, Pivot-Pajot C, Rousseaux S, Khochbin S. 2006. Histone acetylation- mediated chromatin compaction during mouse spermatogenesis. Ernst Schering Res. Found. Workshop 2006:155-72
38. Pivot-Pajot C, Caron C, Govin J, Vion A, Rousseaux S, Khochbin S. 2003. Acetylation-dependent chromatin reorganization byBRDT, a testis-specific bromodomain-containing protein. Mol. Cell Biol. 23:5354-65 (Pubitemid 36950890)
39. Grisolano JL, O'Neal J, Cain J, Tomasson MH. 2003. An activated receptor tyrosine kinase, TEL/PDGFR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc. Natl. Acad. Sci. USA 100:9506-11 (Pubitemid 37033958)
40. Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, et al. 2005. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia 19:1361-66 (Pubitemid 41136329)
41. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, et al. 1996. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911-18 (Pubitemid 27019637)
42. Maher B. 2009. Exome sequencing takes centre stage in cancer profiling. Nature 459:146-47
43. Helmlinger D, Hardy S, Abou-Sleymane G, Eberlin A, Bowman AB, et al. 2006. Glutamineexpanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol. 4:e67
44. McCampbell A, Taye AA, Whitty L, Penney E, Steffan JS, Fischbeck KH. 2001. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc. Natl. Acad. Sci. USA 98:15179-84 (Pubitemid 34013989)
45. McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, et al. 2000. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 9:2197-202
46. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, et al. 2001. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-43 (Pubitemid 33009952)
47. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, et al. 2007. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-39 (Pubitemid 46053039)
48. Redner RL, Corey SJ, Rush EA. 1997. Differentiation of t(5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid. Leukemia 11:1014-16 (Pubitemid 27345950)
49. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, et al. 1998. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339:1341-48 (Pubitemid 28509343)
50. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, et al. 2009. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 106:3342-47
51. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, et al. 2001. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20:5054-58 (Pubitemid 32769795)
52. Paez JG, J'anne PA, Lee JC, Tracy S, Greulich H, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-500 (Pubitemid 38720929)
53. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:561-66
54. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, et al. 2010. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-99
55. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, et al. 2010. Selective inhibition of BET bromodomains. Nature 468:1067-73
56. Adya N, Stacy T, Speck NA, Liu PP. 1998. The leukemic protein core binding factor (CBF)-smoothmuscle myosin heavy chain sequesters CBF2 into cytoskeletal filaments and aggregates. Mol. Cell Biol. 18:7432-43 (Pubitemid 28533062)
57. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, et al. 2010. Suppression of inflammation by a synthetic histone mimic. Nature 468:1119-23
58. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, et al. 2000. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J. Natl. Cancer Inst. 92:1355-57 (Pubitemid 30660597)